Search
+
    SEARCHED FOR:

    CAPITOL HILL VACCINE DEBATE

    How Russian cancer vaccines EnteroMix and personalized mRNA work to control the life-threatening disease

    Russia's cancer vaccine, comprising EnteroMix and personalized mRNA vaccines, has completed preclinical trials, showcasing safety and high efficacy. Research conducted by the NMRRC demonstrated tumor size reduction and slowed progression, ranging from 60% to 80%, alongside increased survival rates. The vaccines aim to destroy malignant cells and activate the patient's antitumor immunity.

    US probes malware email targeting trade talks with China: Report

    The malware in the email that appeared to be sent by Representative John Moolenaar in July to U.S. trade groups, law firms and government agencies was traced by cyber analysts to a hacker group - APT41 - believed to be working for Chinese intelligence, the newspaper said.

    US probes malware email targeting trade talks with China, WSJ reports

    U.S. authorities are investigating a bogus email, disguised as being from Representative John Moolenaar, that contained malware. Cyber analysts traced the malware to APT41, a hacker group believed to be working for Chinese intelligence. The email targeted U.S. trade groups, law firms, and government agencies, potentially seeking insights into U.S.-China trade talks, prompting an FBI investigation.

    A 100% effective cancer vaccine? Russia’s Enteromix achieves success in trials; Here’s the full report you need to read

    Russia's Enteromix vaccine has demonstrated 100% efficacy in preclinical trials, showing promise in fighting tumors. The vaccine, initially targeting colorectal cancer, has shown significant tumor reduction and improved survival rates. Researchers are also developing versions for glioblastoma and melanoma, potentially revolutionizing cancer treatment.

    'Answer my question first!': RFK Jr.'s ultra-heated clash with Senators over mRNA COVID vaccines
    Russian vaccine for colon cancer ready to use: Report

    Russia's Federal Medical Biological Agency (FMBA) has announced the successful completion of preclinical trials for its cancer vaccine, demonstrating safety and high efficacy. The vaccine, initially targeting colorectal cancer, showed significant reductions in tumor size and improved survival rates. Further advancements are being made in developing vaccines for glioblastoma and melanoma.

    The Economic Times
    BACK TO TOP